Here are the S-1 registration statements from MapLight Therapeutics, Inc. (MPLT) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-1 covers the registration statement a company files to sell shares publicly, so if you follow MPLT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MPLT filings page.
MapLight Therapeutics, Inc. (MPLT) filed Amendment No. 1 to a Form S-1 to register for resale up to 13,181,055 shares of voting common stock, consisting of 9,197,887 shares and 3,983,168 shares issuable upon exercise of outstanding pre-funded warrants issued in an August 2026 private placement. The amendment is primarily to correct the number of shares outstanding as of September 1, 2026 and does not register any additional securities. The selling stockholders, including entities such as Catalyst4, Inc. and other institutional investors, may sell their shares from time to time through various methods, and MapLight will not receive proceeds from these resales, other than any nominal cash proceeds if the pre-funded warrants are exercised at their $0.0001 per share exercise price. As context, MapLight previously received approximately $150.0 million in gross proceeds from the private placement that created these securities and had 55,575,719 shares of common stock outstanding as of September 1, 2026.
MapLight Therapeutics, Inc. (MPLT) is registering for resale by existing investors up to 13,181,055 shares of voting common stock, including shares issuable upon exercise of pre-funded warrants, that were issued in an August 2026 private placement. The company itself is not selling shares in this registration and will not receive proceeds from selling stockholders’ sales, other than any nominal cash paid to exercise the pre-funded warrants.
MapLight is a clinical-stage biopharmaceutical company developing circuit-specific therapies for central nervous system disorders. Lead candidate ML-007C-MA, targeting M1/M4 muscarinic receptors, has shown positive topline Phase 2 results in schizophrenia (ZEPHYR), and the company plans an end-of-Phase 2 FDA meeting to discuss a Phase 3 trial supporting an initial NDA. A separate Phase 2 trial (VISTA) in Alzheimer’s disease psychosis is underway with topline results expected in the second half of 2027. Second product candidate ML-004 is in development for autism spectrum disorder symptoms, with Phase 2 results guiding upcoming regulatory discussions and potential partnerships.
The August 2026 private placement that created these resale shares raised $150.0 million in gross proceeds for MapLight through the sale of common stock and pre-funded warrants. As of September 1, 2026, there were 64,773,606 shares of common stock outstanding, and MPLT traded at $13.95 per share on September 8, 2026 on the Nasdaq Global Select Market. The prospectus notes that, once this registration is effective, the ability of selling stockholders to freely resell these shares could increase the volume of stock available for trading and affect the market price.